1-3 of 3
Craig M. Hill, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S. Khodadoust, MD PhD, Tatyana A. Feldman, MD, Dok Hyun Yoon, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Dejan Radeski, MBBS, FRACP, FRCPA, Youn H. Kim, MD, Neha Mehta-Shah, MD, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Ryan A. Wilcox, MD, Won Seog Kim, MD PhD, Steven M. Horwitz, MD, Joseph J. Buggy, PhD, Andrew Hotson, PhD, Craig M. Hill, PhD, Brian Munneke, PhD, Suresh Mahabhashyam, MD, Richard A. Miller, MD, James W. Janc, PhD, Mehrdad Mobasher, MDMPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-137782
Published: 2020
Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-137631
Published: 2020
Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1571.
https://doi.org/10.1182/blood-2019-127338
Published: 2019